SCHEMBL5366852

SCHEMBL5366852

Cc1cc(C=C2C(=O)Nc3ccc(Br)c(C)c32)ccc1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 4/20 0.50
PLK4 O00444 2/20 0.50
MAP1LC3B Q9GZQ8 3/20 0.43
RET P07949 1/20 0.43
RAF1 P04049 5/20 0.42
SIRT1 Q96EB6 2/20 0.42
MEN1 O00255 2/20 0.41
MAPT P10636 2/20 0.41
KMT2A Q03164 2/20 0.41
ALDH1A1 P00352 1/20 0.41
NOX4 Q9NPH5 1/20 0.41
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41
APH1B Q8WW43 1/20 0.41
NCSTN Q92542 1/20 0.41
APH1A Q96BI3 1/20 0.41
PSENEN Q9NZ42 1/20 0.41
EGFR P00533 1/20 0.41
NTRK1 P04629 1/20 0.41
ARAF P10398 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5363090 0.91 LRRK2 (0.60) LRRK2PLK4MAP1LC3BRAF1SIRT1
SCHEMBL5358360 0.86 LRRK2 (0.47) LRRK2PLK4MAP1LC3BRAF1SIRT1
SCHEMBL7136800 0.85 MAP1LC3B (0.56) LRRK2PLK4MAP1LC3BRAF1SIRT1
SCHEMBL5363311 0.84 GSK3B (0.50) LRRK2PLK4MEN1MAPTKMT2A
SCHEMBL7138253 0.84 KDM1A (0.54) LRRK2PLK4RETMEN1MAPT
SCHEMBL7137544 0.84 LRRK2 (0.49) LRRK2PLK4MAP1LC3BRETRAF1
SCHEMBL5363511 0.83 PIM1 (0.53) LRRK2PLK4SIRT1MEN1MAPT
SCHEMBL7138342 0.83 ALDH1A1 (0.53) LRRK2PLK4RETMEN1MAPT
SCHEMBL7139926 0.83 LRRK2 (0.42) LRRK2PLK4MAP1LC3BRAF1SIRT1
SCHEMBL5358709 0.83 MAP1LC3B (0.63) LRRK2PLK4MAP1LC3BRAF1SIRT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK LRRK2 289/4885PLK4 42/4885MAP1LC3B 1427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.